Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin vs High-dose Daunorubicin in AML (AIvsAD)
NCT01145846Phase 3Unknown
- Sponsor
- Japan Adult Leukemia Study Group
- Start
- May 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of idarubicin and daunorubicin in acute myeloid leukemia (AML), sponsored by Japan Adult Leukemia Study Group. Status: unknown.
02
Drugs
idarubicindaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01145846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145846.